Innate Pharma (IPHA) Consolidated Net Income (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Consolidated Net Income data on file, last reported at -$24.2 million in Q2 2025.

• For the quarter ending Q2 2025, Consolidated Net Income rose 9.4% year-over-year to -$24.2 million; the trailing twelve-month figure through Dec 2025 stood at -$103.7 million (down 19.11% YoY), and the FY2022 full-year result was -$132632.2, up 98.42% from the prior year.
• Consolidated Net Income for Q2 2025 stood at -$24.2 million, up from -$52.9 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $7.5 million in Q2 2021 and bottomed at -$52.9 million in Q4 2024.
• The 5-year median for Consolidated Net Income is -$8.1 million (2023), against an average of -$12.5 million.
• Peak annual rise in Consolidated Net Income reached 894.03% in 2023, while the deepest fall reached 6093965.51% in 2023.
• A 5-year view of Consolidated Net Income shows it stood at -$8.4 million in 2021, then soared by 100.0% to -$133.65 in 2022, then slumped by 6093965.51% to -$8.1 million in 2023, then slumped by 549.05% to -$52.9 million in 2024, then surged by 54.3% to -$24.2 million in 2025.
• The last three Consolidated Net Income figures came in at -$24.2 million (Q2 2025), -$52.9 million (Q4 2024), and -$26.7 million (Q2 2024), per Business Quant data.

Peer Comparison